Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...
Shares of Novo Nordisk slipped in Monday morning trading ... a synthetic version of the hormone amylin, which is released by the pancreas. Cagrilintide is currently being developed in combination ...
5d
MedPage Today on MSNEndocrine Society's New President-Elect; Judge Stops Compounders; New GLP-1 BenefitsFalling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide ...
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
6don MSN
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
The new PenCycle programme covers Novo Nordisk's FlexPen and FlexTouch ... and an 'at home' collection service for people using growth hormone pens. "These pens are made from high-quality, long ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results